



SPARC/Sec/SE/2023-24/067

November 06, 2023

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

*Scrip Symbol: SPARC*

*Scrip Code: 532872*

Dear Sir/ Madam,

**Sub: Outcome of the Board Meeting held today i.e. November 06, 2023**

---

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we hereby intimate that the Board of Directors of the Company at its meeting held today i.e. November 06, 2023, *inter alia*, have considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023.

Pursuant to Regulation 30 and 33 of the Listing Regulations, we hereby enclose the Unaudited Financial Results of the Company, for the quarter and half year ended September 30, 2023 along with the Limited Review Report, issued by the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company commenced at 11:30 a.m. and concluded at 03:00 p.m.

This is for your information and dissemination.

For **Sun Pharma Advanced Research Company Ltd.**

**Chetan Rajpara**  
**Chief Financial Officer**


Encl: As above

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Sun Pharma Advanced Research Company Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the "Company") for the quarter ended September 30, 2023 and year to date from April 1, 2023 to September 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003

  
per Amit Singh  
Partner

Membership No.: 408869

UDIN: 23408869BGXKOU4619



Place of Signature: Mumbai  
Date: November 06, 2023


**Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2023**

| Particulars                                                                                                          | Quarter ended  |                |                | Half Year ended |                 | ₹ in Lakhs            |
|----------------------------------------------------------------------------------------------------------------------|----------------|----------------|----------------|-----------------|-----------------|-----------------------|
|                                                                                                                      | 30.09.2023     | 30.06.2023     | 30.09.2022     | 30.09.2023      | 30.09.2022      | Year ended            |
|                                                                                                                      | Unaudited      | Unaudited      | Unaudited      | Unaudited       | Unaudited       | 31.03.2023<br>Audited |
| Revenue from operations                                                                                              | 2,118          | 2,395          | 3,154          | 4,513           | 6,000           | 23,878                |
| Other income                                                                                                         | 849            | 1,019          | 6              | 1,868           | 24              | 1,088                 |
| <b>Total income</b>                                                                                                  | <b>2,967</b>   | <b>3,414</b>   | <b>3,160</b>   | <b>6,381</b>    | <b>6,024</b>    | <b>24,966</b>         |
| <b>Expenses</b>                                                                                                      |                |                |                |                 |                 |                       |
| Cost of materials consumed                                                                                           | 647            | 517            | 558            | 1,164           | 1,128           | 2,211                 |
| Employee benefits expense                                                                                            | 3,071          | 3,112          | 2,593          | 6,183           | 5,143           | 10,699                |
| Clinical trial expenses / products development expense (Refer Note 2)                                                | 1,821          | 3,698          | 2,730          | 5,519           | 6,037           | 14,947                |
| Professional charges                                                                                                 | 4,188          | 4,135          | 2,375          | 8,323           | 5,539           | 13,195                |
| Finance costs                                                                                                        | 26             | 26             | 286            | 52              | 449             | 763                   |
| Depreciation and amortisation expense                                                                                | 318            | 310            | 300            | 628             | 570             | 1,177                 |
| Other expenses                                                                                                       | 1,538          | 1,151          | 1,158          | 2,689           | 2,233           | 4,232                 |
| <b>Total expenses</b>                                                                                                | <b>11,609</b>  | <b>12,949</b>  | <b>10,000</b>  | <b>24,558</b>   | <b>21,099</b>   | <b>47,224</b>         |
| <b>Profit / (loss) before tax</b>                                                                                    | <b>(8,642)</b> | <b>(9,535)</b> | <b>(6,840)</b> | <b>(18,177)</b> | <b>(15,075)</b> | <b>(22,258)</b>       |
| Tax expense                                                                                                          | -              | -              | -              | -               | -               | -                     |
| <b>Profit / (loss) for the period</b>                                                                                | <b>(8,642)</b> | <b>(9,535)</b> | <b>(6,840)</b> | <b>(18,177)</b> | <b>(15,075)</b> | <b>(22,258)</b>       |
| <b>Other comprehensive income (OCI)</b>                                                                              |                |                |                |                 |                 |                       |
| Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan) | 34             | 34             | 43             | 68              | 85              | 135                   |
| <b>Total comprehensive profit / (loss) for the period</b>                                                            | <b>(8,608)</b> | <b>(9,501)</b> | <b>(6,797)</b> | <b>(18,109)</b> | <b>(14,990)</b> | <b>(22,123)</b>       |
| Paid-up equity share capital (Face value ₹ 1 each)                                                                   | 3,245          | 3,245          | 2,719          | 3,245           | 2,719           | 3,245                 |
| Other equity                                                                                                         |                |                |                |                 |                 | 48,032                |
| Basic and diluted earning / (loss) per equity share of ₹ 1 each                                                      | (2.66)         | (2.94)         | (2.52)         | (5.60)          | (5.54)          | (7.82)                |
|                                                                                                                      | Not annualised | Not annualised | Not annualised | Not annualised  | Not annualised  | Annualised            |
| See accompanying notes to the unaudited standalone financial results                                                 |                |                |                |                 |                 |                       |


**Notes :**

- The above unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the 'Company') have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on November 6, 2023 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company.
- During the year ended March 31, 2023, the Company had paused the development of SC0-120 program due to changing clinical landscape. Pursuant to this, the Company had made provision for committed costs for this program estimated amounting to ₹2,700 lakhs. During the current quarter, basis the final settlement, the Company has reversed an excess provision of ₹324 lakhs.
- The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- Previous period figures have been regrouped / reclassified, wherever necessary.

For and on behalf of the Board

  
 Dilip S. Shanghvi  
 Chairman

Mumbai, November 6, 2023



**Sun Pharma Advanced Research Company Limited**

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,

Manjusar, Vadodara - 391 775. Tel. : +91-2667 666800


CIN : L73100GJ2006PLC047837. Website : www.sparc.life

**Statement of Unaudited Standalone Assets and Liabilities as at September 30, 2023**

| Particulars                                                                              | ₹ in Lakhs                       |                                |
|------------------------------------------------------------------------------------------|----------------------------------|--------------------------------|
|                                                                                          | As at<br>30.09.2023<br>Unaudited | As at<br>31.03.2023<br>Audited |
| <b>ASSETS</b>                                                                            |                                  |                                |
| <b>(A) Non-current assets</b>                                                            |                                  |                                |
| (a) Property, plant and equipment                                                        | 10,822                           | 10,541                         |
| (b) Capital work-in-progress                                                             | 233                              | 187                            |
| (c) Other intangible assets                                                              | 28                               | 34                             |
| (d) Intangible assets under development                                                  | 2,513                            | 2,513                          |
| (e) Financial assets                                                                     |                                  |                                |
| (i) Bank balance other than cash and cash equivalents                                    | -                                | 15,000                         |
| (ii) Other financial assets                                                              | 2,538                            | 2,741                          |
| (f) Deferred tax assets (net)                                                            | -                                | -                              |
| (g) Income tax assets (net)                                                              | 6,502                            | 6,260                          |
| (h) Other non-current assets                                                             | 48                               | 241                            |
| <b>Total non-current assets (A)</b>                                                      | <b>22,484</b>                    | <b>37,517</b>                  |
| <b>(B) Current assets</b>                                                                |                                  |                                |
| (a) Financial assets                                                                     |                                  |                                |
| (i) Investments                                                                          | 15,142                           | 29,090                         |
| (ii) Trade receivables                                                                   | 3,170                            | 3,271                          |
| (iii) Cash and cash equivalents                                                          | 131                              | 58                             |
| (iv) Bank balances other than (ii) above                                                 | 21,337                           | 11,099                         |
| (v) Loans                                                                                | 18                               | 54                             |
| (vi) Other financial assets                                                              | 1,242                            | 634                            |
| (b) Other current assets                                                                 | 3,217                            | 1,289                          |
| <b>Total current assets (B)</b>                                                          | <b>44,257</b>                    | <b>45,495</b>                  |
| <b>TOTAL ASSETS</b>                                                                      | <b>66,741</b>                    | <b>83,012</b>                  |
| <b>EQUITY AND LIABILITIES</b>                                                            |                                  |                                |
| <b>Equity</b>                                                                            |                                  |                                |
| (a) Equity share capital                                                                 | 3,245                            | 3,245                          |
| (b) Other equity                                                                         | 29,923                           | 48,032                         |
| <b>Total equity</b>                                                                      | <b>33,168</b>                    | <b>51,277</b>                  |
| <b>Liabilities</b>                                                                       |                                  |                                |
| <b>(A) Non-current liabilities</b>                                                       |                                  |                                |
| (a) Financial liabilities                                                                |                                  |                                |
| (i) Lease liabilities                                                                    | 1,108                            | 1,262                          |
| (b) Provisions                                                                           | 860                              | 814                            |
| (c) Other non-current liabilities                                                        | 10,349                           | 11,765                         |
| <b>Total non-current liabilities (A)</b>                                                 | <b>12,317</b>                    | <b>13,841</b>                  |
| <b>(B) Current liabilities</b>                                                           |                                  |                                |
| (a) Financial liabilities                                                                |                                  |                                |
| (i) Borrowings                                                                           | -                                | 5                              |
| (ia) Lease liabilities                                                                   | 313                              | 300                            |
| (ii) Trade payables                                                                      |                                  |                                |
| - Total outstanding dues of micro enterprises and small enterprises                      | 98                               | 221                            |
| - Total outstanding dues of creditors other than micro enterprises and small enterprises | 16,893                           | 14,605                         |
| (iii) Other financial liabilities                                                        | 2,647                            | 1,173                          |
| (b) Other current liabilities                                                            | 1,017                            | 941                            |
| (c) Provisions                                                                           | 488                              | 649                            |
| <b>Total current liabilities (B)</b>                                                     | <b>21,256</b>                    | <b>17,894</b>                  |
| <b>Total liabilities</b>                                                                 | <b>33,573</b>                    | <b>31,735</b>                  |
| <b>TOTAL EQUITY AND LIABILITIES</b>                                                      | <b>66,741</b>                    | <b>83,012</b>                  |

SIGNED FOR IDENTIFICATION  
BY   
S R B C & CO LLP  
MUMBAI






**Statement of Unaudited Standalone Cash Flow for Half Year Ended September 30, 2023**

| Particulars                                                                                                                                            | ₹ in Lakhs                       |                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------|
|                                                                                                                                                        | Half Year<br>ended<br>30.09.2023 | Half Year<br>ended<br>30.09.2022 |
|                                                                                                                                                        | Unaudited                        | Unaudited                        |
| <b>A. Cash flow from operating activities</b>                                                                                                          |                                  |                                  |
| Loss before tax                                                                                                                                        | (18,177)                         | (15,075)                         |
| <b>Adjustments to reconcile loss before tax to net cash flows:</b>                                                                                     |                                  |                                  |
| Depreciation and amortisation expense                                                                                                                  | 628                              | 570                              |
| Gain on disposal of property, plant and equipment (net)                                                                                                | (3)                              | (11)                             |
| Finance costs                                                                                                                                          | 52                               | 448                              |
| Interest income                                                                                                                                        | (1,654)                          | (1)                              |
| Net gain on sale of financial assets measured at fair value through profit or loss                                                                     | (172)                            | (9)                              |
| Net gain arising on financial assets measured at fair value through profit or loss                                                                     | (24)                             | -                                |
| Net unrealised foreign exchange loss                                                                                                                   | 428                              | 430                              |
| Provision for doubtful debt                                                                                                                            | 205                              | -                                |
| <b>Operating (loss) / profit before working capital changes</b>                                                                                        | <b>(18,717)</b>                  | <b>(13,648)</b>                  |
| <b>Working capital adjustments :</b>                                                                                                                   |                                  |                                  |
| (Increase) / decrease in trade receivables                                                                                                             | (98)                             | (709)                            |
| (Increase) / decrease in other assets                                                                                                                  | (1,909)                          | (763)                            |
| Increase / (decrease) in trade payables                                                                                                                | 1,916                            | 4,685                            |
| Increase / (decrease) in other liabilities                                                                                                             | (204)                            | 152                              |
| Increase / (decrease) in provisions                                                                                                                    | (48)                             | (12)                             |
| <b>Cash used in operations</b>                                                                                                                         | <b>(19,060)</b>                  | <b>(10,295)</b>                  |
| Direct tax (paid) / refund received (including interest on refunds) (net)                                                                              | (243)                            | (26)                             |
| <b>Net cash used in operating activities (A)</b>                                                                                                       | <b>(19,303)</b>                  | <b>(10,321)</b>                  |
| <b>B. Cash flow from investing activities</b>                                                                                                          |                                  |                                  |
| Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development) | (504)                            | (812)                            |
| Proceeds from disposal of property, plant and equipment                                                                                                | 23                               | 33                               |
| Redemption of investments (net)                                                                                                                        | 14,144                           | 975                              |
| Fixed deposits with bank placed                                                                                                                        | (2,500)                          | -                                |
| Fixed deposits with bank matured                                                                                                                       | 7,262                            | -                                |
| Interest received                                                                                                                                      | 1,120                            | 2                                |
| <b>Net cash generated from investing activities (B)</b>                                                                                                | <b>19,545</b>                    | <b>198</b>                       |
| <b>C. Cash flow from financing activities</b>                                                                                                          |                                  |                                  |
| Proceeds from borrowings                                                                                                                               | 190                              | 15,868                           |
| Re-payment of borrowings                                                                                                                               | (195)                            | (5,116)                          |
| Payment of lease liabilities                                                                                                                           | (163)                            | (154)                            |
| Interest paid                                                                                                                                          | (1)                              | (378)                            |
| <b>Net cash generated / (used in) financing activities (C)</b>                                                                                         | <b>(169)</b>                     | <b>10,220</b>                    |
| <b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>                                                                                  | <b>73</b>                        | <b>97</b>                        |
| Cash and cash equivalents at the beginning of the year                                                                                                 | 58                               | 122                              |
| <b>Cash and cash equivalents at the end of the period</b>                                                                                              | <b>131</b>                       | <b>219</b>                       |

SIGNED FOR IDENTIFICATION  
 BY  
  
 SRBC & CO LLP  
 MUMBAI







Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Sun Pharma Advanced Research Company Limited

- 1 We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of Sun Pharma Advanced research Company Limited (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), for the quarter ended September 30, 2023 and year to date from April 1, 2023 to September 30, 2023 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

| Name of the entity | Relationship |
|--------------------|--------------|
| SPARCLIFE, INC.    | Subsidiary   |

(This space is intentionally left blank)



# SRBC & CO LLP


Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
  - One subsidiary, whose interim financial results and other financial information include total assets of Rs. Nil as at September 30, 2023, and total revenues of Rs. Nil, total net profit after tax of Rs. Nil, total comprehensive loss of Rs. Nil, for the quarter ended and half year ended September 30, 2023, and the period ended on that date and net cash inflows of Rs. Nil for the period from April 01, 2023, to September 30, 2023.

The unaudited interim financial results and other unaudited financial information of this subsidiary have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of this subsidiary, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to the financial results and information certified by the Management.

For SRBC & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003



per Amit Singh  
Partner  
Membership No.: 408869

UDIN: 23408869BGXKOV4802

Place of Signature: Mumbai  
Date: November 06, 2023



**Sun Pharma Advanced Research Company Limited**

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,

Manjusar, Vadodara - 391 775. Tel. : +91-2667 666800

CIN : L73100GJ2006PLC047837. Website : www.sparc.life

**Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year  
Ended September 30, 2023**


| Particulars                                                                                                          | ₹ in Lakhs     |                 |
|----------------------------------------------------------------------------------------------------------------------|----------------|-----------------|
|                                                                                                                      | Quarter ended  | Half Year ended |
|                                                                                                                      | 30.09.2023     | 30.09.2023      |
|                                                                                                                      | Unaudited      | Unaudited       |
| Revenue from operations                                                                                              | 2,118          | 4,513           |
| Other income                                                                                                         | 849            | 1,868           |
| <b>Total income</b>                                                                                                  | <b>2,967</b>   | <b>6,381</b>    |
| <b>Expenses</b>                                                                                                      |                |                 |
| Cost of materials consumed                                                                                           | 647            | 1,164           |
| Employee benefits expense                                                                                            | 3,071          | 6,183           |
| Clinical trial expenses / products development expense (Refer Note 4)                                                | 1,821          | 5,519           |
| Professional charges                                                                                                 | 4,188          | 8,323           |
| Finance costs                                                                                                        | 26             | 52              |
| Depreciation and amortisation expense                                                                                | 318            | 628             |
| Other expenses                                                                                                       | 1,538          | 2,689           |
| <b>Total expenses</b>                                                                                                | <b>11,609</b>  | <b>24,558</b>   |
| <b>Profit / (loss) before tax</b>                                                                                    | <b>(8,642)</b> | <b>(18,177)</b> |
| Tax expense                                                                                                          | -              | -               |
| <b>Profit / (loss) for the period</b>                                                                                | <b>(8,642)</b> | <b>(18,177)</b> |
| <b>Other comprehensive income (OCI)</b>                                                                              |                |                 |
| Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan) | 34             | 68              |
| <b>Total comprehensive profit / (loss) for the period</b>                                                            | <b>(8,608)</b> | <b>(18,109)</b> |
| <b>Attributable to:</b>                                                                                              |                |                 |
| - Owners of the Company                                                                                              | <b>(8,608)</b> | <b>(18,109)</b> |
| Paid-up equity share capital (Face value ₹ 1 each)                                                                   | 3,245          | 3,245           |
| Other equity                                                                                                         |                |                 |
| Basic and diluted earning / (loss) per equity share of ₹ 1 each                                                      | (2.66)         | (5.60)          |
|                                                                                                                      | Not annualised | Not annualised  |

See accompanying notes to the unaudited consolidated financial results

**Notes :**

- The unaudited consolidated financial results relate to Sun Pharma Advance Research Company Limited (the 'Company') and its Subsidiary (together the 'Group') are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- The Company has formed a wholly owned subsidiary in USA named 'SPARCLIFE Inc.' on September 25, 2023. The subsidiary is yet to commence the business operations and there are no transactions during the period under review. The financial results for the quarter and half year ended September 30, 2023 do not present comparable information with that of earlier periods.
- The above unaudited consolidated financial results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on November 6, 2023 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company
- During the year ended March 31, 2023, the Group had paused the development of SC0-120 program due to changing clinical landscape. Pursuant to this, the Group had made provision for committed costs for this program estimated amounting to ₹2,700 lakhs. During the current quarter, basis the final settlement, the Group has reversed an excess provision of ₹324 lakhs.
- The Group has only one reportable business segment namely 'Pharmaceutical Research & Development'.

For and on behalf of the Board

  
Dilip S. Shanghvi  
Chairman

Mumbai, November 6, 2023





**Sun Pharma Advanced Research Company Limited**

Regd. Office: Plot No. 5 & 6/I, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,

Manjusar, Vadodara - 391 775. Tel. : +91-2667 666800

CIN : L73100GJ2006PLC047837. Website : www.spare.life

**Statement of Unaudited Consolidated Assets and Liabilities as at September 30, 2023**

| Particulars                                                                              | ₹ in Lakhs                       |
|------------------------------------------------------------------------------------------|----------------------------------|
|                                                                                          | As at<br>30.09.2023<br>Unaudited |
| <b>ASSETS</b>                                                                            |                                  |
| <b>(A) Non-current assets</b>                                                            |                                  |
| (a) Property, plant and equipment                                                        | 10,622                           |
| (b) Capital work-in-progress                                                             | 233                              |
| (c) Other intangible assets                                                              | 28                               |
| (d) Intangible assets under development                                                  | 2,513                            |
| (e) Financial assets                                                                     |                                  |
| (i) Other financial assets                                                               | 2,538                            |
| (f) Deferred tax assets (net)                                                            | -                                |
| (g) Income tax assets (net)                                                              | 6,502                            |
| (h) Other non-current assets                                                             | 48                               |
| <b>Total non-current assets (A)</b>                                                      | <b>22,484</b>                    |
| <b>(B) Current assets</b>                                                                |                                  |
| (a) Financial assets                                                                     |                                  |
| (i) Investments                                                                          | 15,142                           |
| (ii) Trade receivables                                                                   | 3,170                            |
| (iii) Cash and cash equivalents                                                          | 131                              |
| (iv) Bank balances other than (iii) above                                                | 21,337                           |
| (v) Loans                                                                                | 18                               |
| (vi) Other financial assets                                                              | 1,242                            |
| (b) Other current assets                                                                 | 3,217                            |
| <b>Total current assets (B)</b>                                                          | <b>44,257</b>                    |
| <b>TOTAL ASSETS</b>                                                                      | <b>66,741</b>                    |
| <b>EQUITY AND LIABILITIES</b>                                                            |                                  |
| <b>Equity</b>                                                                            |                                  |
| (a) Equity share capital                                                                 | 3,245                            |
| (b) Other equity                                                                         | 29,923                           |
| <b>Equity attributable to owners of the Company</b>                                      | <b>33,168</b>                    |
| <b>Total Equity</b>                                                                      | <b>33,168</b>                    |
| <b>Liabilities</b>                                                                       |                                  |
| <b>(A) Non-current liabilities</b>                                                       |                                  |
| (a) Financial liabilities                                                                |                                  |
| (i) Lease liabilities                                                                    | 1,108                            |
| (b) Provisions                                                                           | 860                              |
| (c) Other non-current liabilities                                                        | 10,349                           |
| <b>Total non-current liabilities (A)</b>                                                 | <b>12,317</b>                    |
| <b>(B) Current liabilities</b>                                                           |                                  |
| (a) Financial liabilities                                                                |                                  |
| (i) Lease liabilities                                                                    | 313                              |
| (ii) Trade payables                                                                      |                                  |
| - Total outstanding dues of micro enterprises and small enterprises                      | 98                               |
| - Total outstanding dues of creditors other than micro enterprises and small enterprises | 16,693                           |
| (iii) Other financial liabilities                                                        | 2,647                            |
| (b) Other current liabilities                                                            | 1,017                            |
| (c) Provisions                                                                           | 488                              |
| <b>Total current liabilities (B)</b>                                                     | <b>21,256</b>                    |
| <b>Total liabilities</b>                                                                 | <b>33,573</b>                    |
| <b>TOTAL EQUITY AND LIABILITIES</b>                                                      | <b>66,741</b>                    |

SIGNED FOR IDENTIFICATION  
BY  
SR  
SRBC & CO LLP  
MUMBAI



*S. R. B. C.*

**Sun Pharma Advanced Research Company Limited**  
 Regd. Office: Plot No. 5 & 6/1, Savli, G. I.D.C. Estate, Savli - Vadodara Highway,  
 Manjusar Vadodara - 391 775. Tel. : +91-2667 666800  
 CIN : L73100GJ2006PLC047837. Website : www.sparc.life

**Statement of Unaudited Consolidated Cash Flow for Half Year Ended September 30, 2023**

| Particulars                                                                                                                                            | ₹ in Lakhs                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
|                                                                                                                                                        | Half Year<br>ended<br>30.09.2023<br>Unaudited |
| <b>A. Cash flow from operating activities</b>                                                                                                          |                                               |
| Loss before tax                                                                                                                                        | (18,177)                                      |
| <b>Adjustments to reconcile loss before tax to net cash flows:</b>                                                                                     |                                               |
| Depreciation and amortisation expense                                                                                                                  | 628                                           |
| Gain on disposal of property, plant and equipment (net)                                                                                                | (3)                                           |
| Finance costs                                                                                                                                          | 52                                            |
| Interest income                                                                                                                                        | (1,654)                                       |
| Net gain on sale of financial assets measured at fair value through profit or loss                                                                     | (172)                                         |
| Net gain arising on financial assets measured at fair value through profit or loss                                                                     | (24)                                          |
| Net unrealised foreign exchange loss                                                                                                                   | 428                                           |
| Provision for doubtful debt                                                                                                                            | 205                                           |
| <b>Operating (loss) / profit before working capital changes</b>                                                                                        | <b>(18,717)</b>                               |
| <b>Working capital adjustments :</b>                                                                                                                   |                                               |
| (Increase) / decrease in trade receivables                                                                                                             | (98)                                          |
| (Increase) / decrease in other assets                                                                                                                  | (1,909)                                       |
| Increase / (decrease) in trade payables                                                                                                                | 1,916                                         |
| Increase / (decrease) in other liabilities                                                                                                             | (204)                                         |
| Increase / (decrease) in provisions                                                                                                                    | (48)                                          |
| <b>Cash used in operations</b>                                                                                                                         | <b>(19,060)</b>                               |
| Direct tax (paid) / refund received (including interest on refunds) (net)                                                                              | (243)                                         |
| <b>Net cash used in operating activities (A)</b>                                                                                                       | <b>(19,303)</b>                               |
| <b>B. Cash flow from investing activities</b>                                                                                                          |                                               |
| Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development) | (504)                                         |
| Proceeds from disposal of property, plant and equipment                                                                                                | 23                                            |
| Redemption of investments (net)                                                                                                                        | 14,144                                        |
| Fixed deposits with bank placed                                                                                                                        | (2,500)                                       |
| Fixed deposits with bank matured                                                                                                                       | 7,252                                         |
| Interest received                                                                                                                                      | 1,120                                         |
| <b>Net cash generated from investing activities (B)</b>                                                                                                | <b>19,545</b>                                 |
| <b>C. Cash flow from financing activities</b>                                                                                                          |                                               |
| Proceeds from borrowings                                                                                                                               | 190                                           |
| Re-payment of borrowings                                                                                                                               | (195)                                         |
| Payment of lease liabilities                                                                                                                           | (163)                                         |
| Interest paid                                                                                                                                          | (1)                                           |
| <b>Net cash used in financing activities (C)</b>                                                                                                       | <b>(169)</b>                                  |
| <b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>                                                                                  | <b>73</b>                                     |
| Cash and cash equivalents at the beginning of the year                                                                                                 | 58                                            |
| <b>Cash and cash equivalents at the end of the period</b>                                                                                              | <b>131</b>                                    |

SIGNED FOR IDENTIFICATION  
 BY   
 SRBC & COLLP  
 MUMBAI



